Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Labelled Comp Radiopharm. 2018 Mar 12;61(9):636–651. doi: 10.1002/jlcr.3607

FIGURE 2.

FIGURE 2

A, Simplified decay scheme of 64Cu (data taken from the National Nuclear Data Center: www.nndc.bnl.gov), B, schematic overview of 64Cu-labeled antibody using DOTA as chelator, and C, 64Cu-DOTA-trastuzumab PET images of HER2-positive metastatic brain lesions (arrows) (This research was originally published in JNM. Tamura K et al. 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. J Nucl Med 2013; 54:1869–1875. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.)